HOME >> MEDICINE >> NEWS
Emselex(R) receives positive CHMP opinion for the treatment of overactive bladder

Basel, 30th July 2004 Novartis Pharma AG announced today that the Committee for Medicinal Products for Human Use (CHMP), adopted a positive opinion recommending that the European Commission (EC) grant a Marketing Authorisation for Emselex (darifenacin hydrobromide), 7.5mg and 15mg, for the treatment of overactive bladder (OAB) in all 25 European Union (EU) countries as well as Norway and Iceland. Upon receipt of the EC approval, Novartis will be able to market Emselex throughout these countries.

"We are delighted by the CHMP's positive opinion for Emselex, to provide overactive bladder sufferers with a new safe and effective treatment option", said Jrg Reinhardt, Global Head of Development Novartis Pharma AG. "Due to its M3 selectivity, Emselex provides effective overactive bladder symptom relief while decreasing the potential risk of safety issues such as cognitive impairment or effects on cardiac function."

OAB affects almost one in six adults in Europe1. Symptoms of overactive bladder are urinary urgency (a sudden compelling desire to pass urine, which is difficult to defer) with or without urge incontinence (involuntary leakage accompanied by urgency), urinary frequency (voiding the bladder too often), and nocturia (waking at night one or more times to void the bladder).

The CHMP based its positive opinion on Emselex's comprehensive data package for OAB. The safety and efficacy of Emselex has been extensively studied in over 90 pre-clinical studies and clinical trials, involving more than 5,000 patients. Pivotal studies explored key endpoints including the reduction in the number of incontinence episodes per week, the reduction in the number of voluntary urination episodes (micturition) per day, the reduction in the episodes and severity of urgency and an increase in the average volume of urine passed per micturition.

The phase III clinical
'"/>


30-Jul-2004


Page: 1 2 3

Related medicine news :

1. UIC professor receives international humanitarian award
2. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
3. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
4. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
5. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
6. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program
7. American Academy of Neurology program receives Grassroots Award
8. Orqis receives FDA approval to expand clinical trial of Cancion CRS therapy to 40 centers
9. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
10. Pfizers antifungal medicine VFEND receives FDA approval
11. Shire receives US FDA approval of EQUETRO (TM) for bipolar disorder

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/17/2017)... ... February 17, 2017 , ... ... services, announced today that Karen Pilley has been promoted to Chief Executive Officer. ... today’s shifting healthcare paradigm – a shift that demands the transition from pay-for-service ...
(Date:2/17/2017)... ... February 17, 2017 , ... Like most hospitals across the nation, Onslow Memorial ... by the Hospital Readmission Reduction Program (HRRP), the return of a patient to the ... across the nation. While many providers are struggling to leverage limited resources and technology, ...
(Date:2/16/2017)... ... February 17, 2017 , ... ... took over 10 years of research, development and clinical trials, the founder of ... is a patented compound of FDA approved ingredients that when infused into alcohol, ...
(Date:2/16/2017)... ... February 16, 2017 , ... ... and superiority in patient care, NWH has achieved Magnet® recognition for ... Tuesday, January 31, 2017. The American Nurses Credentialing Center’s Magnet Recognition Program® distinguishes ...
(Date:2/16/2017)... ... February 16, 2017 , ... A February 6 ... as fat freezing or CoolSculpting, noting that some 425,000 procedures were performed with the ... that the clinic is, in fact, seeing a great deal of interest from area ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... YORK , Feb. 17, 2017  Noble Capital ... on ESSA Pharma Inc. (Nasdaq: EPIX ). ... Research, Kumar Raja , PhD. ESSA ... for castration resistant prostate cancer (CRPC). Its lead compound ... blocks the amino-terminal domain of the androgen receptor, thereby ...
(Date:2/16/2017)... , Feb. 16, 2017 The global ... USD 7.88 billion by 2021 from USD 5.49 billion ... On the basis of type, the preparative and ... preparative chromatography. In 2016, the process chromatography segment is ... global preparative and process chromatography. Growth in this segment ...
(Date:2/16/2017)... , Feb. 16, 2017  AcelRx Pharmaceuticals, Inc. ... company focused on the development and commercialization of ... pain, announced that Vincent J. Angotti ... member of the company,s board of directors, effective ... two decades of experience leading executive and commercial ...
Breaking Medicine Technology:
Cached News: